Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:01:53 EST Sun 08 Feb 2026
Enter Symbol
or Name
USA
CA



Q:CDTX - CIDARA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CDTX - QHALTED221.38    221.41  15.22Jan 06Nov 2415 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-11-24 08:00U:CDTXNews ReleaseCidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
2025-11-06 16:07U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
2025-10-28 08:00U:CDTXNews ReleaseCidara Therapeutics to Participate in November Investor Conferences
2025-10-23 16:05U:CDTXNews ReleaseCidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025
2025-10-23 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025
2025-10-21 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025
2025-10-13 08:00U:CDTXNews ReleaseCidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
2025-10-10 08:00U:CDTXNews ReleaseCidara Therapeutics to Present at 10th ESWI Influenza Conference 2025
2025-10-09 08:00U:CDTXNews ReleaseCidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza Prevention
2025-10-02 16:01U:CDTXNews ReleaseCidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative Therapeutic
2025-09-25 16:01U:CDTXNews ReleaseCidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk Populations
2025-09-24 07:00U:CDTXNews ReleaseCidara Therapeutics Announces Expanded and Accelerated Phase 3 Plan for CD388, a Non-Vaccine Preventative of Seasonal Influenza
2025-09-17 08:00U:CDTXNews ReleaseCidara Therapeutics Presents Data on CD388 from its Phase 2b NAVIGATE Trial and Preclinical Studies Against H5N1 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting
2025-09-04 08:00U:CDTXNews ReleaseCidara Therapeutics to Participate in September Investor Conferences
2025-09-03 08:00U:CDTXNews ReleaseCidara Therapeutics to Present Clinical Phase 2b Data and Preclinical H5N1 Data on CD388 at ISRV's 8th AVG and 3rd IMRP 2025 Meeting
2025-08-07 16:05U:CDTXNews ReleaseCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
2025-07-24 08:00U:CDTXNews ReleaseCidara Therapeutics to Report Second Quarter 2025 Financial Results and Host Quarterly Conference Call on August 7, 2025
2025-07-01 17:00U:CDTXNews ReleaseCidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2025-06-30 08:00U:CDTXNews ReleaseCidara Therapeutics Announces Inclusion in the Russell 2000(TM) and Russell 3000(TM) Indexes
2025-06-26 17:15U:CDTXNews ReleaseCidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares